“Botox in a jar” in Panama: Argireline, the evidence and the marketing

In Panama, the phrase “Botox in a cream” appears on labels, social media and aesthetic consultations to describe cosmetics containing acetyl hexapeptide-8, known as Argireline. The useful question for the physician is twofold: what has science shown about this peptide, and what may a product registered as a cosmetic with the Ministry of Health’s National Directorate of Pharmacy and Drugs (DNFD) legally say? This article separates the two and complements our pieces on SNAP-8 and argireline and signal peptides such as Matrixyl.

What Argireline is and why it is called “Botox in a cream”

Argireline is a synthetic hexapeptide (Ac-EEMQRR-NH2) designed from a fragment of the SNAP-25 protein. Its hypothesis is to interfere with the SNARE complex needed to release the neurotransmitter that contracts muscle, the same point where botulinum toxin acts¹. In the original 2002 work the peptide inhibited neurotransmitter release with a potency similar to botulinum toxin A, but with much lower efficacy, according to the authors themselves¹. Hence the nickname: it shares a target, not a result.

A classic review places it among the neurotransmitter-inhibitor peptides, one of four families of topical peptides for aged skin, alongside signal peptides, enzyme inhibitors and carrier peptides¹⁰. Another review cautions that the benefits of these cosmeceuticals may not be as rigorously tested as those of FDA-regulated drugs, although the evidence is growing¹¹. A 2026 framework for the safety evaluation of cosmetic peptides proposes bioinformatic tools to screen for toxins and allergens and calls for further testing by the industry¹⁶.

What the trials measured

The initial study used an oil-in-water emulsion with 10% peptide in women volunteers and measured skin topography: up to 30% less wrinkle depth after 30 days¹. In a randomized placebo-controlled trial in China, 60 subjects applied Argireline or placebo (3:1) to periorbital wrinkles twice daily for four weeks; overall efficacy was 48.9% versus 0% with placebo, and roughness parameters decreased with the peptide (p < 0.01)².

These are positive results, but with limits the physician should see: short trials (weeks), a single area (the eye contour), few subjects and a partly subjective assessment. A Greek randomized trial of 24 volunteers over 60 days, using a peptide it calls “acetyl hexapeptide-3” combined with tripeptide-10 citrulline, confirmed anti-wrinkle activity and lower transepidermal water loss, but the authors acknowledge the mechanism of the synergy was unclear⁵. Nomenclature for this peptide varies between publications, so the sequence should be checked before comparing studies.

How much peptide crosses the skin

This is the crux. To act like a toxin, the peptide would have to reach the neuromuscular junction, below the dermis. FDA scientists measured it: after 24 hours of exposure to an emulsion with 10% Ac-EEMQRR-amide, nearly all the peptide was washed off the surface; in human skin, 0.22% of the dose remained in the stratum corneum, 0.01% in the epidermis, and no peptide was detected in the dermis or the receptor fluid³. The authors themselves describe the underlying concern: that peptides in cosmetics may penetrate deep layers and stimulate biological activity³.

Formulation matters. An Austrian study in pig skin found that a multiple water-in-oil-in-water emulsion significantly increased penetration compared with simple emulsions, and notes that this peptide’s skin penetration had been sparsely studied and controversially discussed⁴. It is an animal model, not living human skin, and it does not show a clinical effect.

Concentration: 10% in the studies, 0.005% in the safety panel

The US Expert Panel for Cosmetic Ingredient Safety concluded in 2025 that acetyl hexapeptide-8 amide is safe in cosmetics in present practices of use at concentrations up to 0.005%, and that data are insufficient to determine safety above that level⁶. The early efficacy and penetration studies used 10% emulsions¹³: about 2,000 times more. The gap does not show harm, but it forces every result to be read by asking what concentration produced it and whether the product on a Panamanian shelf resembles the trial emulsion.

What a cosmetic may say in Panama

Executive Decree 27 of May 10, 2024, which regulates Law 419, defines a cosmetic as a substance meant to contact the superficial parts of the body to clean, perfume, change the appearance of, protect or keep them in good condition¹³. It requires a sanitary registration to import, manufacture, distribute and sell it (art. 189) and lets the DNFD reject products with harmful or prohibited substances (art. 197)¹³. Law 419 restates that cosmetics need sanitary registration¹⁴. Cosmetic registration was digitized starting in 2022, when the process was still manual and in person¹⁵.

Two articles weigh on “Botox in a cream.” Article 199 establishes that additional information on labels or inserts counts as advertising and must stick strictly to the properties that derive from the formula, and that “the declaration of properties that cannot be proven is prohibited”¹³. Article 208 provides that products that claim to cure a disease, or that can be ingested, inhaled or injected, are not cosmetics, because cosmetics may only be applied topically¹³. In addition, the DNFD monitors the cosmetic market by evaluating labeling (art. 290), and establishments that sell cosmetics must be able to show traceability (art. 346)¹³. Truthfulness of advertising is shared with ACODECO under Law 419¹⁴. As evidence that oversight is real, the DNFD cancelled cosmetic registrations in 2026, per our analysis of the BMHCA case.

The toxin plays in another league

As far as the literature we reviewed goes, we found no trial comparing topical Argireline with botulinum toxin for facial wrinkles. A 2025 review in the Journal of Drugs in Dermatology is titled “Acetyl Hexapeptide-8 as a Topical Alternative to Botulinum Toxin”¹², but its PubMed record has no abstract and we do not cite it for its conclusions. The closest thing to a combined test is a double-blind trial in 24 blepharospasm patients receiving toxin: topical peptide produced no significant adverse events and there was a non-significant trend toward a longer effect (3.7 versus 3.0 months), with 4 of 12 patients showing a considerable extension⁷. That is a neurological disease, not a wrinkle, and the authors say “promising,” not equivalent.

If it is injected, it is no longer a cosmetic

The nickname invites a dangerous leap: injecting the peptide. In a rat model, subdermally injected Argireline produced no detectable tissue-level effect on collagen versus control, whereas the toxin did change the collagen profile⁸. In humans there is a published case of Mycobacterium abscessus infection after Argireline injections in the forehead and temples of a 45-year-old woman, treated with clarithromycin and moxifloxacin for five months⁹. One case cannot estimate risk, but it shows that what Article 208 excludes from the cosmetic category is precisely what gets injected. Who may perform injectable procedures in Panama is covered in our aesthetic medicine article, and the pattern of cosmetic promises with other peptides in GHK-Cu creams and the registration double standard.

How to read a “Botox in a cream”

• Ask for the cosmetic sanitary registration number and check that the product is registered with the DNFD.
• Compare the package promise with what the formula can support (art. 199)¹³.
• Ask the peptide concentration and compare it with the 0.005% assessed by the safety panel⁶.
• Tell placebo-controlled trials apart from pig-skin or cadaver-skin studies³⁴.
• Be wary of any injectable presentation of a cosmetic peptide⁹¹³.